Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
Severe Psoriasis Associated with Lower Income
WASHINGTON--(BUSINESS WIRE)--Feb. 2, 2007--The National Psoriasis
Foundation and Amgen (NASDAQ:AMGN), today announced survey findings
which show that nearly 40 percent of 1,142 patients surveyed with
chronic moderate or severe psoriasis are not currently receiving any
treatment. These results were presented at the American Academy of
Dermatology (AAD) Scientific Meeting in Washington, D.C.
According to AAD therapy guidelines, patients diagnosed with
chronic moderate to severe plaque psoriasis are candidates for
phototherapy or systemic therapy, including biologic agents. Despite
the increased number of psoriasis treatment options, the findings show
no significant change in treatment patterns across three survey years.
According to further data presented at AAD, based on National
Psoriasis Foundation surveys from 2003 to 2005, more than half of
moderate to severe patients on treatment are not being treated as
recommended by AAD guidelines. Of those treated, 57 percent of
patients with severe psoriasis (n=459) and 73 percent of patients with
moderate psoriasis (n=683) are receiving topical treatment alone.
"Psoriasis is not a cosmetic disease, but rather a chronic
inflammatory condition that can have a profound negative impact on a
person's ability to function," said Mark Lebwohl, M.D., chairman of
the National Psoriasis Foundation Medical Board. "It's important for
patients to openly discuss with their dermatologist how the condition
may be impacting them, so that together they can determine the most
appropriate treatment option."
According to additional survey findings, severe psoriasis is
associated with lower income. Data presented at AAD show that 21
percent of patients with severe psoriasis (n=179) had a low household
income (less than $30,000), compared to 13 percent for patients with
mild psoriasis (n=180).
"These are the first data to show a relationship between psoriasis
severity and household income," said Liz Horn, Ph.D., director of
research, National Psoriasis Foundation. "Psoriasis is a serious
disease that can significantly impact a patient's life by interfering
with everyday activities, including work. Further research will be
valuable in supporting these data and will hopefully lead to the
improved treatment of psoriasis."
Data from semi-annual patient surveys conducted by the National
Psoriasis Foundation from 2003 to 2005 were combined and analyzed to
study treatment patterns for psoriasis patients. Psoriasis severity
was assessed using patient-reported affected body surface area (BSA)
and was defined as mild (less than 3 percent BSA), moderate (3-10
percent BSA), or severe (greater than 10 percent BSA). A separate
analysis was conducted in patients greater than 30 years of age to
study the relationship between psoriasis severity and household
income. The research was funded by the National Psoriasis Foundation,
Amgen and Wyeth Pharmaceuticals.
Psoriasis is a non-contagious, chronic disease, in which the
immune system causes the skin to grow at an accelerated rate.
According to the National Institutes of Health, up to 7.5 million
people in the United States suffer from psoriasis. The disease occurs
among people of all ages, although it is most commonly diagnosed in
early adulthood. Types of psoriasis include plaque, guttate, pustular,
inverse, and erythrodermic. Due to genetic factors, certain people are
more likely to develop psoriasis, but a "trigger" is usually necessary
to make psoriasis appear. These triggers may include emotional stress,
injury to the skin, some types of infection, or reaction to certain
About the National Psoriasis Foundation
The National Psoriasis Foundation is the leading patient-driven,
nonprofit organization dedicated to improving the quality of life for
millions of Americans with psoriasis and/or psoriatic arthritis, and
their families. The Psoriasis Foundation focuses on education,
advocacy and research toward better treatments and a cure. For more
information, please call the National Psoriasis Foundation,
headquartered in Portland, Ore., at 800-723-9166, or visit
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe,
effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: National Psoriasis Foundation
Paula Fasano, 503-546-8413
Sonia Fiorenza, 805-447-1604 (media)
Arvind Sood, 805-447-1060 (investors)